Clinical Outcomes Research Office, Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine in St Louis, St Louis, Missouri, USA.
School of Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.
Otolaryngol Head Neck Surg. 2023 Dec;169(6):1654-1661. doi: 10.1002/ohn.477. Epub 2023 Aug 25.
Develop and validate a quality-of-life (QoL) outcome measure for patients with dysosmia.
Cross-sectional survey study.
Otolaryngology clinics, research registries, and Facebook support groups.
A 59-item pilot survey with questions addressing parosmia concerns was developed using input from subjects with parosmia and clinical expertise from Otolaryngologists. After item reduction, the Parosmia Olfactory Dysfunction Outcomes Rating (DisODOR) was reduced to its final 29 items. DisODOR maximum score is 116 (each item score 0-4) with higher scores indicating a higher degree of dysfunction from smell distortion. DisODOR was validated using participants with parosmia persisting >3 months after severe acute respiratory syndrome coronavirus 2 (cases) and healthy controls. Reliability, face and content validity, internal consistency, convergent validity, discriminative validity, sensitivity to change, and the minimal clinically important difference (MCID) were assessed.
A total of 134 cases and 20 controls completed DisODOR. The mean (SD) age was 45.9 (12.2) for cases and 29.6 (8.9) for controls. The mean score difference between cases and controls was 45.0 (95% confidence interval, 40.5-49.5) displaying good discriminative validity. DisODOR showed strong test-retest reliability (r = .942) with high internal consistency (Cronbach's α = .971). DisODOR had a moderate correlation with SNOT-22 scores (r = .619) indicating good convergent validity. There is an excellent association with the global impression of severity categories (η = 0.447). Based on the distribution method, the MCID is 15.
DisODOR is a valid, reliable QoL instrument for parosmia that can be used to measure the functional impact and QoL impairment for parosmia patients. DisODOR is sensitive to change and thus can be used in studies investigating treatments for parosmia.
为嗅觉障碍患者开发和验证生活质量（QoL）结局测量工具。
横断面调查研究。
耳鼻喉科诊所、研究登记处和 Facebook 支持小组。
使用嗅觉障碍患者的输入和耳鼻喉科医生的临床专业知识，开发了一个包含 59 个项目的试点调查，这些问题涉及到嗅觉障碍的担忧。经过项目缩减，嗅觉障碍嗅觉功能障碍结局评分（DisODOR）缩减为最终的 29 个项目。DisODOR 的最大得分为 116（每个项目得分为 0-4），得分越高表明嗅觉扭曲导致的功能障碍程度越高。使用 SARS-CoV-2 后持续 3 个月以上的嗅觉障碍患者（病例）和健康对照者对 DisODOR 进行验证。评估了可靠性、表面和内容有效性、内部一致性、收敛有效性、判别有效性、对变化的敏感性以及最小临床重要差异（MCID）。
共有 134 例病例和 20 例对照完成了 DisODOR。病例的平均（SD）年龄为 45.9（12.2），对照组为 29.6（8.9）。病例与对照组之间的平均得分差异为 45.0（95%置信区间，40.5-49.5），显示出良好的判别有效性。DisODOR 具有良好的重测信度（r=.942）和较高的内部一致性（Cronbach's α=.971）。DisODOR 与 SNOT-22 评分中度相关（r=.619），表明具有良好的收敛有效性。与整体严重程度类别具有极好的相关性（η=0.447）。根据分布方法，MCID 为 15。
DisODOR 是一种用于嗅觉障碍的有效、可靠的生活质量工具，可用于测量嗅觉障碍患者的功能影响和生活质量受损情况。DisODOR 对变化敏感，因此可用于研究嗅觉障碍的治疗方法。
